Facebook
Twitter
LinkedIn
WhatsApp

Stage 4 Cancer

Stage 4, Stage IV metastatic cancer

“Metastases cancer” or stage 4 cancer, is the medical term for describing a condition where a tumor originating in a certain organ, “primary tumor”, is identified in another organ or in a distant location from the original organ, e.g., metastases of breast cancer can be found in the lungs, brain, bones and liver.

It is important to note, metastases are the same type of the original primary tumor, even if its location is in distant organs and so are the treatments regarded as such, for example, a treatment for a metastatic lung cancer that has spread to the liver, is determined by the treatment for metastatic lung cancer and not by the treatment for liver cancer.

Metastases formation

Cancer cells of the primary tumor can be released into the bloodstream and lymphatic system and circulate to distant organs or adjacent organs and tissues to the primary tumor and “settle” in them and grow.

There are different types of cancer which is known where metastases can be formed, for example,

  • Breast cancer can spread to the bones, brain, liver and lungs
  • Lung cancer can spread to the brain, bones, liver and kidney
  • Prostate cancer can spread to the bones
  • Colon cancer, rectal cancer, colorectal cancer can spread to the liver and lungs
Breast cancer can spread to the bones, brain, liver and lungs
Breast cancer can spread to the bones, brain, liver and lungs

Stage IV metastatic cancer and recovery

In the vast majority of the metastatic cases, the treatments do not cure. Treatment goals are slowing tumor growth rate, prolonging life and reducing the symptoms of the disease, improving the quality of life of the patient.

The efficacy of the treatments is affected by many factors, among them are the type of cancer, number of metastases (also called “lesions”) and their location, how much cancer the patient has in his or her body, growth rate of the tumor lesions, medical history of the patient, background diseases, microenvironment between the tumor cells themselves, resistance the tumor has developed to previous treatments and other.

Advanced treatments and clinical trials for stage 4

The National Cancer Institute (NCI) highlights the fact that for a certain group of metastatic cancer patients, the best treatment option is to join one of the many clinical trials existing worldwide aiming to increase their chances of therapeutic success.

This is also recommended by the USA national comprehensive cancer network, NCCN,  (USA national comprehensive cancer network)

“Patients with cancer should be encouraged to participate in clinical trials during all aspects of their diagnosis and treatment”

Currently, every patient will be offered the standard protocols described above. Sometimes the oncologist may suggest integrating these therapies with trials carried out in the Institute.

Advances in cancer therapies may be found in clinical trials prescribing cutting edge, interesting drugs, some of which have already been recognized by the FDA (US Food & Drug Administration) as “breakthrough treatments” and require further information input before being finally and fully approved.

An entire world of clinical trials and compassionate drugs and treatments are open and available worldwide. It is important to know which cutting edge treatments exist which patients can gain far more from them than the standard care offered.

For most patients with stage 4 metastatic cancer, current treatments are insufficiently effective. This gives rise to the need for innovative strategies with greater efficacy in fighting the disease.

Read our publications on innovative treatments for stage 4 metastatic cancer:

To check if our service suits your case
We need to talk

Improve therapeutic outcomes, prolong life and quality of life, is our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics

Facebook
Twitter
LinkedIn
WhatsApp

Meet Zongertinib (Hernexeos) – a breakthrough drug for patients with HER2‑mutant lung cancer

Meet Zongertinib (Hernexeos) – a breakthrough drug for patients with HER2‑mutant lung cancer

Zongertinib (brand name: Hernexeos) is an innovative oral medication that acts as a selective HER2 receptor inhibitor and is intended for patients with non‑squamous NSCLC lung cancer who carry a HER2 mutation in the TKD domain.

The drug was approved by the FDA in August 2025 via an accelerated process, for patients who have already undergone at least one systemic treatment for their disease.

🔬 What did the studies show?
In the BEAMION LUNG‑1 phase 1a/1b study – an overall response rate (ORR) of approximately 71%–75%.
Durable response (DOR) was seen among patients who had not received prior ADC treatment.
Even among patients previously treated with HER2‑targeted ADC drugs – a response was observed (ORR of approx. 44%).

💊 Safety profile
Most side effects were mild (grade 1–2).
Most common: diarrhea (51%), rash (27%).
No cases of interstitial lung disease (ILD) were reported – a known issue with ADC‑type therapies.

Why is it important?

This is an effective, convenient, and safe treatment that offers new hope to patients with HER2‑mutant lung cancer. The drug is taken orally – unlike intravenous therapies – and provides a significant response with a chance to improve both life expectancy and quality of life.

Talk to us so we can help you find and access the most advanced and researched drugs and treatments in the world – for you.

Trial‑In Pharma
Because we don’t give up on life!

📞 24/7 Call Center: 072‑3902977


Read more (FDA & BI official sources):
FDA grants accelerated approval to zongertinib for non‑squamous NSCLC with HER2 TKD activating mutations – official FDA announcement from August 2025 on the accelerated approval of Zongertinib (Hernexeos) for HER2‑mutant NSCLC lung cancer.
U.S. Food and Drug Administration
https://www.boehringer-ingelheim.com/us/media/press-releases/hernexeos-zongertinib-tablets-gains-accelerated-approval

Abstract Creative concept vector icon of Breath for Web and Mobile Applications isolated on background. Vector illustration template design, Business infographic and social media, origami icons.

No Cost service compatibility check
Please fill in the details and we will back to you as soon as possible

Improving therapeutic success, extending life and quality of life are our main business. We extend to metastatic cancer patients and patients with brain tumors, the most advanced treatment options in the world and the best experts in Israel and abroad.

Article categories

קטגוריות המאמרים

Popular topics